Correlation of Clinical Frailty Scale with IDH mutation and MGMT methylation in high-grade glioma

Correlation of Clinical Frailty Scale with IDH mutation and MGMT methylation in high-grade glioma

Bibliographic Details
Main Authors:	J. Klingenschmid, A. Krigers, C.F. Freyschlag, C. Thomé
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	Brain and Spine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772529421004914

Similar Items

The Clinical Frailty Scale as predictor of overall survival in high-grade glioma patients
by: J. Klingenschmid, et al.
Published: (2021-01-01)

Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data
by: Aleksandrs Krigers, et al.
Published: (2022-12-01)

Correlations of MGMT promoter methylation and IDH1 mutations with the clinical prognosis of malignant glioma patients
by: ZHANG Ning, MA Hui-hui, WANG Fan, LIANG Wei, WANG Yi-chun, WU Bing-shan, LI Qing-xin
Published: (2021-10-01)

The relationship between IDH, P53 mutations, MGMT methylation with characteristics in high grade glioma patients
by: Duc Anh Tran, et al.
Published: (2022-07-01)

An assessment of predictive factors for overall survival in glioblastoma – MGMT methylation is solely important for younger patients
by: T. Cosar, et al.
Published: (2022-01-01)

The Clinical Frailty Scale is superior to the Karnofsky Performance Status as predictor of overall survival in patients with surgical treatment of brain metastases
by: N. Pichler, et al.
Published: (2022-01-01)

Intraoperative Raman Spectroscopy for real-time characterisation of IDH mutation and MGMT methylation status of adult Gliomas
by: Babar Vaqas, et al.
Published: (2023-01-01)

Temporal muscle thickness has no prognostic relevance in patients with high-grade glioma compared to functional scales
by: Julia Klingenschmid, et al.
Published: (2023-08-01)

Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
by: Magda Sayed Mahmoud, et al.
Published: (2024-03-01)

Clinical Frailty Scale and Karnofsky Performance Status are Superior to Temporal Muscle Thickness in Survival Prediction in Brain Metastasis Patients
by: Aleksandrs Krigers, et al.
Published: (2023-01-01)

Surgical Management of Malignant Glioma in the Elderly
by: Julia Klingenschmid, et al.
Published: (2022-05-01)

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI
by: Yongjian Sha, et al.
Published: (2023-02-01)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status
by: Jae Kyung Myung, et al.
Published: (2014-12-01)

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment
by: Julius July, et al.
Published: (2020-08-01)

Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO grade 2 and 3 gliomas
by: Aleksandrs Krigers, et al.
Published: (2021-08-01)

Isocitrate dehydrogenase 1 and 2 genes mutations and MGMT methylation in gliomas
by: D. V. Tabakov, et al.
Published: (2017-04-01)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
by: Nguyen Quoc Khanh Le, et al.
Published: (2020-09-01)

XGBoost improves classification of MGMT promoter methylation status in IDH1 wildtype glioblastoma
by: Le, Nguyen Quoc Khanh, et al.
Published: (2021)

Research and application progress of MGMT promoter methylation in gliomas
by: Cui-yun SUN, et al.
Published: (2014-07-01)

Impact of GAP-43 and actin expression on the outcome and overall survival in diffuse and anaplastic gliomas
by: A. Krigers, et al.
Published: (2022-01-01)

Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
by: Ke Wang, et al.
Published: (2021-11-01)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
by: Valentin Karl Ladenhauf, et al.
Published: (2023-02-01)

Research progress of IDH1 and IDH2 mutations in gliomas
by: Shan-shan ZHANG, et al.
Published: (2015-11-01)

Prognostic significance of MGMT promoter methylation in diffuse glioma patients
by: Nikola Jovanović, et al.
Published: (2019-01-01)

Application of MGMT Promoter Methylation of Cerebrospinal Fluid in Diagnosis of Glioma
by: WANG Long, et al.
Published: (2018-10-01)

<it>MGMT </it>promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
by: Håvik Annette, et al.
Published: (2012-03-01)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
by: Mirri Maria, et al.
Published: (2009-03-01)

MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [<sup>18</sup>F]FDOPA Uptake in Primary Brain Tumors
by: Andrea Cimini, et al.
Published: (2020-10-01)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
by: Fatih Incekara, et al.
Published: (2020-05-01)

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
by: Simone Kreth, et al.
Published: (2011-02-01)

Promoter methylation analysis of IDH genes in human gliomas
by: Simon eFlanagan, et al.
Published: (2012-12-01)

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
by: Fumiharu Ohka, et al.
Published: (2011-01-01)

The Significance of <i>MGMT</i> Promoter Methylation Status in Diffuse Glioma
by: Nikola Jovanović, et al.
Published: (2022-10-01)

Retrospective study on MGMT methylation status and its clinical significance in gliomas
by: JIANG Lin, LIU Qiying, JIA Liqing, ZHANG Jing, CHANG Heng, XUE Tian, REN Min, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan
Published: (2023-08-01)

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
by: Emir, U, et al.
Published: (2015)

Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India
by: Suvendu Purkait, et al.
Published: (2016-08-01)

The Potential Effect of the IDH1 Mutation and MGMT Gene Promoter Methylation on the Control of Glioblastoma-Associated Epilepsy in Patients Receiving Anti-Epileptic Agents and Chemotherapies
by: Maher KURDI, et al.
Published: (2021-09-01)

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
by: Pasquale Persico, et al.
Published: (2022-02-01)

Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma
by: Kang H, et al.
Published: (2020-10-01)

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
by: Yuan Gu, et al.
Published: (2020-10-01)